| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Philips reiterates its confidence in delivering the full-year 2025 outlook: • Comparable sales growth: 1%-3% • Adjusted EBITA margin: 11.3%-11.8%, now expected toward the upper end of the range • Free cash flow: EUR 0.2-0.4 billion (including the payout in the first quarter of 2025 of EUR 1,025 million Philips Respironics recall-related medical monitoring and personal injury settlements in the US.) This outlook excludes ongoing Philips Respironics-related proceedings, including the investigation by the US Department of Justice.
Posted In: PHG
